# Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

> **NCT03418558** · PHASE2 · UNKNOWN · sponsor: **Fondazione del Piemonte per l'Oncologia** · enrollment: 13 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT03418558
- **Lead sponsor:** Fondazione del Piemonte per l'Oncologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07-08
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03418558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03418558, "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03418558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*